Literature DB >> 18585421

In vivo activity of cationic immune stimulating complexes (PLUSCOMs).

Warren T McBurney1, Dirk G Lendemans, Julia Myschik, Tania Hennessy, Thomas Rades, Sarah Hook.   

Abstract

A particulate vaccine delivery system consisting of cationic ISCOM derivatives (PLUSCOMs) was compared to classic anionic ISCOMs with regard to antigen attachment and ability to elicit in vivo T cell responses against a model protein antigen (ovalbumin [OVA]). ISCOMs did not incorporate hydrophilic OVA whilst OVA readily adsorbed onto PLUSCOMs with increasing adsorption at higher protein concentrations. The zeta-potential of PLUSCOMs significantly decreased with increasing protein load, suggesting neutralization of the cationic charge upon absorption of the anionic OVA. Antigen-specific CD8 T cell responses were demonstrated in mice vaccinated with either PLUSCOMs or ISCOMs. Ex vivo restimulation of harvested T cells demonstrated that cells isolated from PLUSCOM and ISCOM vaccinated mice responded to the secondary OVA challenge more efficiently than mice vaccinated with OVA in solution. Restimulated cells from the mice vaccinated with particulate vaccines produced significantly more INF-gamma. Therefore PLUSCOMs are as effective as classic ISCOMs in inducing antigen-specific CD8 T cell responses and have advantages with regard to the incorporation of purified anionic antigens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585421     DOI: 10.1016/j.vaccine.2008.06.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  In vitro cutaneous application of ISCOMs on human skin enhances delivery of hydrophobic model compounds through the stratum corneum.

Authors:  Henriette Baun Madsen; Peter Ifversen; Flemming Madsen; Birger Brodin; Ingrid Hausser; Hanne Mørck Nielsen
Journal:  AAPS J       Date:  2009-10-28       Impact factor: 4.009

Review 2.  Development of a universal CTL-based vaccine for influenza.

Authors:  Diego Esteban Cargnelutti; María Victoria Sánchez; Nora Marta Mattion; Eduardo Alberto Scodeller
Journal:  Bioengineered       Date:  2013-01-21       Impact factor: 3.269

3.  Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines.

Authors:  Sharan Bobbala; Viral Tamboli; Arlene McDowell; Ashim K Mitra; Sarah Hook
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

Review 4.  Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?

Authors:  Sharan Bobbala; Sarah Hook
Journal:  Pharm Res       Date:  2016-07-05       Impact factor: 4.580

5.  An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.

Authors:  Aiala Salvador; Manoli Igartua; Rosa Maria Hernández; José Luis Pedraz
Journal:  J Drug Deliv       Date:  2011-06-15

Review 6.  COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology.

Authors:  Hyun Jee Han; Chinekwu Nwagwu; Obumneme Anyim; Chinedu Ekweremadu; San Kim
Journal:  Int Immunopharmacol       Date:  2020-12-02       Impact factor: 4.932

Review 7.  Nanotechnology: an emerging approach to combat COVID-19.

Authors:  Anjani Devi Chintagunta; Sai Krishna M; Sanjana Nalluru; Sampath Kumar N S
Journal:  Emergent Mater       Date:  2021-02-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.